Gout treatment and comorbidities: a retrospective cohort study in a large US managed care population View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2011-12

AUTHORS

Paola Primatesta, Estel Plana, Dietrich Rothenbacher

ABSTRACT

BACKGROUND: Gout prevalence increased in recent years to become one of the most common causes of inflammatory arthritis in most industrialised countries. Comorbidities may affect the disease severity and treatment patterns. We describe the main characteristics of gout patients, gout-related treatment patterns and prevalent comorbidities in a managed care population. METHODS: From the large US PharMetrics Patient-Centric Database, patients aged 20-89 with at least 2 claims for a diagnosis of gout (ICD9 274.xx) and related prescriptions between January 1, 1996 and December 31, 2008 were included. Gout flares were ascertained during follow-up. Sex-specific multivariable Poisson regression models were used to assess factors associated with number of flares. RESULTS: 177,637 gout patients were included (mean age 55.2 years; men 75.6%). Overall, more than half (58.1%) had any of the considered comorbidities; hypertension (36.1%), dyslipidemia (27.0%) and diabetes (15.1%) being the most common. Nonselective NSAIDs were the most commonly dispensed (in 38.7% of patients). Notably, 39% of patients did not receive any prescription medication for gout. Patients with comorbidities were significantly more likely to receive anti-gout prescriptions. During an acute episode the prescription of NSAIDs and colchicine increased; and 29.9% of patients received allopurinol. The risk of flares was associated with cardiometabolic comorbidities and older age in women (highest at age 60-69), while in men it decreased by age. Women with these conditions were 60% more likely to have flares (incidence rate ratio, IRR 1.60;1.48-1.74), while men were 10% (IRR 1.10; 1.06-1.13) more likely. CONCLUSIONS: Comorbidities affected gout treatment patterns and the occurrence and frequency of acute attacks. Cardiometabolic comorbidities, common in this patients' population, were associated with an increased risk of flares. More... »

PAGES

103

References to SciGraph publications

  • 2006-04. The inflammatory process of gout and its treatment in ARTHRITIS RESEARCH & THERAPY
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1186/1471-2474-12-103

    DOI

    http://dx.doi.org/10.1186/1471-2474-12-103

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1009476891

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/21599917


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Clinical Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Adult", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Aged", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Aged, 80 and over", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Comorbidity", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Databases as Topic", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Drug Prescriptions", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Female", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Gout", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Gout Suppressants", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Insurance, Pharmaceutical Services", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Male", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Managed Care Programs", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Middle Aged", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Practice Patterns, Physicians'", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Prevalence", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Recurrence", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Retrospective Studies", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Risk Assessment", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Risk Factors", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Severity of Illness Index", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Sex Factors", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Time Factors", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Treatment Outcome", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "United States", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Young Adult", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Novartis (Switzerland)", 
              "id": "https://www.grid.ac/institutes/grid.419481.1", 
              "name": [
                "Global Clinical Epidemiology, Novartis Pharma AG, CH-4056, Basel, Switzerland"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Primatesta", 
            "givenName": "Paola", 
            "id": "sg:person.0746071036.29", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0746071036.29"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Novartis (Spain)", 
              "id": "https://www.grid.ac/institutes/grid.476612.0", 
              "name": [
                "Global Clinical Epidemiology, Novartis Farmac\u00e9utica SA, Barcelona, Spain"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Plana", 
            "givenName": "Estel", 
            "id": "sg:person.01170754651.51", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01170754651.51"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "University of Ulm", 
              "id": "https://www.grid.ac/institutes/grid.6582.9", 
              "name": [
                "Institute for Epidemiology and Medical Biometry, University of Ulm, Ulm, Germany"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Rothenbacher", 
            "givenName": "Dietrich", 
            "id": "sg:person.01153404427.25", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01153404427.25"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "https://doi.org/10.1136/ard.2007.078469", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1000554853"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1136/pgmj.2004.030692", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1004164212"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1136/pgmj.2004.030692", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1004164212"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1136/ard.2007.070755", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1008431174"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1136/ard.2004.024091", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1010425509"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.4065/81.7.925", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1015946021"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1097/01.rhu.0000209882.50228.9f", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1022343040"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1097/01.rhu.0000209882.50228.9f", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1022343040"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1097/01.rhu.0000209882.50228.9f", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1022343040"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1097/bor.0b013e3282f4eff5", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1028919668"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1097/bor.0b013e3282f4eff5", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1028919668"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/ar1908", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1028925208", 
              "https://doi.org/10.1186/ar1908"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1001/archinte.168.10.1104", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1029270672"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/s0149-2918(03)80158-3", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1037602895"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/s0149-2918(03)80158-3", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1037602895"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1136/ard.2008.092619", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1040468310"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1002/art.22014", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1040634488"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/s0140-6736(09)60883-7", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1047910298"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1093/rheumatology/kep332", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1048055785"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1093/rheumatology/kem056a", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1052857574"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1136/ard.2006.055251", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1053455934"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://app.dimensions.ai/details/publication/pub.1077136275", 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://app.dimensions.ai/details/publication/pub.1077604945", 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2011-12", 
        "datePublishedReg": "2011-12-01", 
        "description": "BACKGROUND: Gout prevalence increased in recent years to become one of the most common causes of inflammatory arthritis in most industrialised countries. Comorbidities may affect the disease severity and treatment patterns. We describe the main characteristics of gout patients, gout-related treatment patterns and prevalent comorbidities in a managed care population.\nMETHODS: From the large US PharMetrics Patient-Centric Database, patients aged 20-89 with at least 2 claims for a diagnosis of gout (ICD9 274.xx) and related prescriptions between January 1, 1996 and December 31, 2008 were included. Gout flares were ascertained during follow-up. Sex-specific multivariable Poisson regression models were used to assess factors associated with number of flares.\nRESULTS: 177,637 gout patients were included (mean age 55.2 years; men 75.6%). Overall, more than half (58.1%) had any of the considered comorbidities; hypertension (36.1%), dyslipidemia (27.0%) and diabetes (15.1%) being the most common. Nonselective NSAIDs were the most commonly dispensed (in 38.7% of patients). Notably, 39% of patients did not receive any prescription medication for gout. Patients with comorbidities were significantly more likely to receive anti-gout prescriptions. During an acute episode the prescription of NSAIDs and colchicine increased; and 29.9% of patients received allopurinol. The risk of flares was associated with cardiometabolic comorbidities and older age in women (highest at age 60-69), while in men it decreased by age. Women with these conditions were 60% more likely to have flares (incidence rate ratio, IRR 1.60;1.48-1.74), while men were 10% (IRR 1.10; 1.06-1.13) more likely.\nCONCLUSIONS: Comorbidities affected gout treatment patterns and the occurrence and frequency of acute attacks. Cardiometabolic comorbidities, common in this patients' population, were associated with an increased risk of flares.", 
        "genre": "research_article", 
        "id": "sg:pub.10.1186/1471-2474-12-103", 
        "inLanguage": [
          "en"
        ], 
        "isAccessibleForFree": true, 
        "isPartOf": [
          {
            "id": "sg:journal.1024957", 
            "issn": [
              "1471-2474"
            ], 
            "name": "BMC Musculoskeletal Disorders", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "1", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "12"
          }
        ], 
        "name": "Gout treatment and comorbidities: a retrospective cohort study in a large US managed care population", 
        "pagination": "103", 
        "productId": [
          {
            "name": "readcube_id", 
            "type": "PropertyValue", 
            "value": [
              "2d24c5f5c5d457238cba40809b641b091e337f7745e2e71b9a773bc08ac85cdc"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "21599917"
            ]
          }, 
          {
            "name": "nlm_unique_id", 
            "type": "PropertyValue", 
            "value": [
              "100968565"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1186/1471-2474-12-103"
            ]
          }, 
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1009476891"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1186/1471-2474-12-103", 
          "https://app.dimensions.ai/details/publication/pub.1009476891"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2019-04-10T18:20", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8675_00000510.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "http://link.springer.com/10.1186%2F1471-2474-12-103"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/1471-2474-12-103'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/1471-2474-12-103'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/1471-2474-12-103'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/1471-2474-12-103'


     

    This table displays all metadata directly associated to this object as RDF triples.

    245 TRIPLES      21 PREDICATES      73 URIs      47 LITERALS      35 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1186/1471-2474-12-103 schema:about N132b45e394604aec990239edcabc8635
    2 N159414bc32584cf7917cac609734739d
    3 N1c9e164c43b14e138bf59fff69c7193d
    4 N316fa8b8836f48eeb610edd3d2317bb9
    5 N41b377b0b6464cc7ae53c4967e11e387
    6 N545f195b7cda46e6a5e2f47eca8b1fd8
    7 N56d1e12fc55a40e69368a2fbc5645e72
    8 N63b65dd20df54e94834a43d3acb3ccc7
    9 N641d34c811a24ebcb47cb6d3ebdaaa44
    10 N65f04adce5e0497098276bc10617ba15
    11 N70487ab4540f4c48865289312609b996
    12 N8ec2e7406a894d7b9ffddc9966d7353e
    13 N8f8bdbaac286418fb423e533c2c1f59c
    14 N92d90ecbe72a4d46b7396f118a23bb9c
    15 Naa0c649af2274913b5f9f394337516b0
    16 Naaf1d4512d7141f1a191fd0046248370
    17 Nb9e2e9ea89f848e9854950da7c8a7a50
    18 Nbd3191ca0a5d4e1d9dfd3c95dd50cce4
    19 Nc465b17b4f884474ac1e84d3b26148ce
    20 Nca6e9cf731a0420a9679a3458e1b3eb4
    21 Ne1e458ddfe0d4e35adb26960d78ae2ab
    22 Ne8ab4f26f9834a43bb148e09e2898fa0
    23 Nf4e5c3029c674d1f808497ec0639f424
    24 Nf84fa2f2804447ac9bbf7051e8c8e056
    25 Nfe83215cefe242c0bb73306bd9c72892
    26 Nff313cd4bc5543d191701b49ddb9061b
    27 anzsrc-for:11
    28 anzsrc-for:1103
    29 schema:author Nb5d773e6d9df4e3f90992fa1f827db60
    30 schema:citation sg:pub.10.1186/ar1908
    31 https://app.dimensions.ai/details/publication/pub.1077136275
    32 https://app.dimensions.ai/details/publication/pub.1077604945
    33 https://doi.org/10.1001/archinte.168.10.1104
    34 https://doi.org/10.1002/art.22014
    35 https://doi.org/10.1016/s0140-6736(09)60883-7
    36 https://doi.org/10.1016/s0149-2918(03)80158-3
    37 https://doi.org/10.1093/rheumatology/kem056a
    38 https://doi.org/10.1093/rheumatology/kep332
    39 https://doi.org/10.1097/01.rhu.0000209882.50228.9f
    40 https://doi.org/10.1097/bor.0b013e3282f4eff5
    41 https://doi.org/10.1136/ard.2004.024091
    42 https://doi.org/10.1136/ard.2006.055251
    43 https://doi.org/10.1136/ard.2007.070755
    44 https://doi.org/10.1136/ard.2007.078469
    45 https://doi.org/10.1136/ard.2008.092619
    46 https://doi.org/10.1136/pgmj.2004.030692
    47 https://doi.org/10.4065/81.7.925
    48 schema:datePublished 2011-12
    49 schema:datePublishedReg 2011-12-01
    50 schema:description BACKGROUND: Gout prevalence increased in recent years to become one of the most common causes of inflammatory arthritis in most industrialised countries. Comorbidities may affect the disease severity and treatment patterns. We describe the main characteristics of gout patients, gout-related treatment patterns and prevalent comorbidities in a managed care population. METHODS: From the large US PharMetrics Patient-Centric Database, patients aged 20-89 with at least 2 claims for a diagnosis of gout (ICD9 274.xx) and related prescriptions between January 1, 1996 and December 31, 2008 were included. Gout flares were ascertained during follow-up. Sex-specific multivariable Poisson regression models were used to assess factors associated with number of flares. RESULTS: 177,637 gout patients were included (mean age 55.2 years; men 75.6%). Overall, more than half (58.1%) had any of the considered comorbidities; hypertension (36.1%), dyslipidemia (27.0%) and diabetes (15.1%) being the most common. Nonselective NSAIDs were the most commonly dispensed (in 38.7% of patients). Notably, 39% of patients did not receive any prescription medication for gout. Patients with comorbidities were significantly more likely to receive anti-gout prescriptions. During an acute episode the prescription of NSAIDs and colchicine increased; and 29.9% of patients received allopurinol. The risk of flares was associated with cardiometabolic comorbidities and older age in women (highest at age 60-69), while in men it decreased by age. Women with these conditions were 60% more likely to have flares (incidence rate ratio, IRR 1.60;1.48-1.74), while men were 10% (IRR 1.10; 1.06-1.13) more likely. CONCLUSIONS: Comorbidities affected gout treatment patterns and the occurrence and frequency of acute attacks. Cardiometabolic comorbidities, common in this patients' population, were associated with an increased risk of flares.
    51 schema:genre research_article
    52 schema:inLanguage en
    53 schema:isAccessibleForFree true
    54 schema:isPartOf Ndb57cb985e224ade8a6789ac2fbe0392
    55 Ne07dddf45593488cbaeedd34219b9e75
    56 sg:journal.1024957
    57 schema:name Gout treatment and comorbidities: a retrospective cohort study in a large US managed care population
    58 schema:pagination 103
    59 schema:productId N552046f620ce42cea7c33198fe54cd95
    60 N8bacc67e6f4d470792ef24bf3d562fac
    61 N8d1b4bf62ae54486bb7213ce4163bb50
    62 Ncecc8211461e4310b19442604e77f599
    63 Neb709926a55b4275bce7d589a2654bb9
    64 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009476891
    65 https://doi.org/10.1186/1471-2474-12-103
    66 schema:sdDatePublished 2019-04-10T18:20
    67 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    68 schema:sdPublisher N53a9ef69ceb24bdeadcc309ed6613a7e
    69 schema:url http://link.springer.com/10.1186%2F1471-2474-12-103
    70 sgo:license sg:explorer/license/
    71 sgo:sdDataset articles
    72 rdf:type schema:ScholarlyArticle
    73 N132b45e394604aec990239edcabc8635 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    74 schema:name Middle Aged
    75 rdf:type schema:DefinedTerm
    76 N159414bc32584cf7917cac609734739d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    77 schema:name Retrospective Studies
    78 rdf:type schema:DefinedTerm
    79 N1c9e164c43b14e138bf59fff69c7193d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    80 schema:name Drug Prescriptions
    81 rdf:type schema:DefinedTerm
    82 N316fa8b8836f48eeb610edd3d2317bb9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    83 schema:name United States
    84 rdf:type schema:DefinedTerm
    85 N41b377b0b6464cc7ae53c4967e11e387 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    86 schema:name Databases as Topic
    87 rdf:type schema:DefinedTerm
    88 N4b4e739259954851b75989fb3f2f32b8 rdf:first sg:person.01153404427.25
    89 rdf:rest rdf:nil
    90 N53a9ef69ceb24bdeadcc309ed6613a7e schema:name Springer Nature - SN SciGraph project
    91 rdf:type schema:Organization
    92 N545f195b7cda46e6a5e2f47eca8b1fd8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    93 schema:name Young Adult
    94 rdf:type schema:DefinedTerm
    95 N552046f620ce42cea7c33198fe54cd95 schema:name readcube_id
    96 schema:value 2d24c5f5c5d457238cba40809b641b091e337f7745e2e71b9a773bc08ac85cdc
    97 rdf:type schema:PropertyValue
    98 N56d1e12fc55a40e69368a2fbc5645e72 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    99 schema:name Humans
    100 rdf:type schema:DefinedTerm
    101 N63b65dd20df54e94834a43d3acb3ccc7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    102 schema:name Comorbidity
    103 rdf:type schema:DefinedTerm
    104 N641d34c811a24ebcb47cb6d3ebdaaa44 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    105 schema:name Time Factors
    106 rdf:type schema:DefinedTerm
    107 N65f04adce5e0497098276bc10617ba15 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    108 schema:name Severity of Illness Index
    109 rdf:type schema:DefinedTerm
    110 N70487ab4540f4c48865289312609b996 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    111 schema:name Gout Suppressants
    112 rdf:type schema:DefinedTerm
    113 N8bacc67e6f4d470792ef24bf3d562fac schema:name dimensions_id
    114 schema:value pub.1009476891
    115 rdf:type schema:PropertyValue
    116 N8d1b4bf62ae54486bb7213ce4163bb50 schema:name nlm_unique_id
    117 schema:value 100968565
    118 rdf:type schema:PropertyValue
    119 N8ec2e7406a894d7b9ffddc9966d7353e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    120 schema:name Gout
    121 rdf:type schema:DefinedTerm
    122 N8f8bdbaac286418fb423e533c2c1f59c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    123 schema:name Risk Factors
    124 rdf:type schema:DefinedTerm
    125 N92d90ecbe72a4d46b7396f118a23bb9c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    126 schema:name Treatment Outcome
    127 rdf:type schema:DefinedTerm
    128 Na9eb5d46969047cfbcadeec125185879 rdf:first sg:person.01170754651.51
    129 rdf:rest N4b4e739259954851b75989fb3f2f32b8
    130 Naa0c649af2274913b5f9f394337516b0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    131 schema:name Male
    132 rdf:type schema:DefinedTerm
    133 Naaf1d4512d7141f1a191fd0046248370 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    134 schema:name Risk Assessment
    135 rdf:type schema:DefinedTerm
    136 Nb5d773e6d9df4e3f90992fa1f827db60 rdf:first sg:person.0746071036.29
    137 rdf:rest Na9eb5d46969047cfbcadeec125185879
    138 Nb9e2e9ea89f848e9854950da7c8a7a50 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    139 schema:name Adult
    140 rdf:type schema:DefinedTerm
    141 Nbd3191ca0a5d4e1d9dfd3c95dd50cce4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    142 schema:name Sex Factors
    143 rdf:type schema:DefinedTerm
    144 Nc465b17b4f884474ac1e84d3b26148ce schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    145 schema:name Aged, 80 and over
    146 rdf:type schema:DefinedTerm
    147 Nca6e9cf731a0420a9679a3458e1b3eb4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    148 schema:name Aged
    149 rdf:type schema:DefinedTerm
    150 Ncecc8211461e4310b19442604e77f599 schema:name doi
    151 schema:value 10.1186/1471-2474-12-103
    152 rdf:type schema:PropertyValue
    153 Ndb57cb985e224ade8a6789ac2fbe0392 schema:issueNumber 1
    154 rdf:type schema:PublicationIssue
    155 Ne07dddf45593488cbaeedd34219b9e75 schema:volumeNumber 12
    156 rdf:type schema:PublicationVolume
    157 Ne1e458ddfe0d4e35adb26960d78ae2ab schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    158 schema:name Managed Care Programs
    159 rdf:type schema:DefinedTerm
    160 Ne8ab4f26f9834a43bb148e09e2898fa0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    161 schema:name Prevalence
    162 rdf:type schema:DefinedTerm
    163 Neb709926a55b4275bce7d589a2654bb9 schema:name pubmed_id
    164 schema:value 21599917
    165 rdf:type schema:PropertyValue
    166 Nf4e5c3029c674d1f808497ec0639f424 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    167 schema:name Recurrence
    168 rdf:type schema:DefinedTerm
    169 Nf84fa2f2804447ac9bbf7051e8c8e056 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    170 schema:name Practice Patterns, Physicians'
    171 rdf:type schema:DefinedTerm
    172 Nfe83215cefe242c0bb73306bd9c72892 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    173 schema:name Insurance, Pharmaceutical Services
    174 rdf:type schema:DefinedTerm
    175 Nff313cd4bc5543d191701b49ddb9061b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    176 schema:name Female
    177 rdf:type schema:DefinedTerm
    178 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    179 schema:name Medical and Health Sciences
    180 rdf:type schema:DefinedTerm
    181 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
    182 schema:name Clinical Sciences
    183 rdf:type schema:DefinedTerm
    184 sg:journal.1024957 schema:issn 1471-2474
    185 schema:name BMC Musculoskeletal Disorders
    186 rdf:type schema:Periodical
    187 sg:person.01153404427.25 schema:affiliation https://www.grid.ac/institutes/grid.6582.9
    188 schema:familyName Rothenbacher
    189 schema:givenName Dietrich
    190 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01153404427.25
    191 rdf:type schema:Person
    192 sg:person.01170754651.51 schema:affiliation https://www.grid.ac/institutes/grid.476612.0
    193 schema:familyName Plana
    194 schema:givenName Estel
    195 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01170754651.51
    196 rdf:type schema:Person
    197 sg:person.0746071036.29 schema:affiliation https://www.grid.ac/institutes/grid.419481.1
    198 schema:familyName Primatesta
    199 schema:givenName Paola
    200 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0746071036.29
    201 rdf:type schema:Person
    202 sg:pub.10.1186/ar1908 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028925208
    203 https://doi.org/10.1186/ar1908
    204 rdf:type schema:CreativeWork
    205 https://app.dimensions.ai/details/publication/pub.1077136275 schema:CreativeWork
    206 https://app.dimensions.ai/details/publication/pub.1077604945 schema:CreativeWork
    207 https://doi.org/10.1001/archinte.168.10.1104 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029270672
    208 rdf:type schema:CreativeWork
    209 https://doi.org/10.1002/art.22014 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040634488
    210 rdf:type schema:CreativeWork
    211 https://doi.org/10.1016/s0140-6736(09)60883-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047910298
    212 rdf:type schema:CreativeWork
    213 https://doi.org/10.1016/s0149-2918(03)80158-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037602895
    214 rdf:type schema:CreativeWork
    215 https://doi.org/10.1093/rheumatology/kem056a schema:sameAs https://app.dimensions.ai/details/publication/pub.1052857574
    216 rdf:type schema:CreativeWork
    217 https://doi.org/10.1093/rheumatology/kep332 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048055785
    218 rdf:type schema:CreativeWork
    219 https://doi.org/10.1097/01.rhu.0000209882.50228.9f schema:sameAs https://app.dimensions.ai/details/publication/pub.1022343040
    220 rdf:type schema:CreativeWork
    221 https://doi.org/10.1097/bor.0b013e3282f4eff5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028919668
    222 rdf:type schema:CreativeWork
    223 https://doi.org/10.1136/ard.2004.024091 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010425509
    224 rdf:type schema:CreativeWork
    225 https://doi.org/10.1136/ard.2006.055251 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053455934
    226 rdf:type schema:CreativeWork
    227 https://doi.org/10.1136/ard.2007.070755 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008431174
    228 rdf:type schema:CreativeWork
    229 https://doi.org/10.1136/ard.2007.078469 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000554853
    230 rdf:type schema:CreativeWork
    231 https://doi.org/10.1136/ard.2008.092619 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040468310
    232 rdf:type schema:CreativeWork
    233 https://doi.org/10.1136/pgmj.2004.030692 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004164212
    234 rdf:type schema:CreativeWork
    235 https://doi.org/10.4065/81.7.925 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015946021
    236 rdf:type schema:CreativeWork
    237 https://www.grid.ac/institutes/grid.419481.1 schema:alternateName Novartis (Switzerland)
    238 schema:name Global Clinical Epidemiology, Novartis Pharma AG, CH-4056, Basel, Switzerland
    239 rdf:type schema:Organization
    240 https://www.grid.ac/institutes/grid.476612.0 schema:alternateName Novartis (Spain)
    241 schema:name Global Clinical Epidemiology, Novartis Farmacéutica SA, Barcelona, Spain
    242 rdf:type schema:Organization
    243 https://www.grid.ac/institutes/grid.6582.9 schema:alternateName University of Ulm
    244 schema:name Institute for Epidemiology and Medical Biometry, University of Ulm, Ulm, Germany
    245 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...